What to look out for when using eltrombopag

Medical decision-making needs to be based on scientific understanding and standardized operation.

What to look out for when using eltrombopag

The rational use of drugs for the treatment of thrombocytopenia directly affects the treatment effect.

Dose adjustment needs to be individualized

The initial dose is usually set at 25 mg/day and should be reduced to 12.5 mg in patients with abnormal liver function. Platelet count should be measured weekly during treatment, and the drug should be stopped when the value exceeds 150×10⁹/L. Special populations such as East Asian patients may be more sensitive to drugs, and it is recommended to increase the frequency of monitoring.

Risk of drug interactions

It should be taken at least 4 hours after taking it with polyvalent cationic preparations (containing iron, calcium, and aluminum). Potent CYP3A4 inhibitors may increase plasma levels and require dose adjustment. Concomitant use with anticoagulants may increase the probability of bleeding, and coagulation should be monitored if necessary.

Principles of medication for special populations

Pregnant women should use only when they are clearly needed, and it is recommended to suspend feeding during breastfeeding. Older patients over 65 years of age do not need to adjust the dose, but should be alert to changes in liver function. Children's medication should strictly follow the weight dose calculation formula, and the treatment period should not exceed 6 months.

Standardized medication of eltrombopag

Systematic management, from prescription to follow-up, optimizes treatment outcomes.

Pre-treatment evaluation system

Baseline tests should include screening for liver function tests, serum ferritin, and viral hepatitis. Patients at risk of portal vein thrombosis should be evaluated by vascular ultrasound. The patient's previous medication history, particularly immunosuppressant use, was recorded.

Indicators monitored during treatment

Complete blood count is done weekly for the first 4 weeks and monthly for the first 4 weeks. Liver function tests are performed every 2 weeks, and the drug should be discontinued if there is a 3-fold increase in aminotransferases. Evaluate regularly for signs of myelofibrosis and perform bone marrow biopsies if necessary.

Follow-up observation after discontinuation of the drug

Platelet count should be monitored continuously for at least 4 weeks after completion of treatment. Some patients may have rebound thrombocytopenia and an emergency plan is required. Establish long-term follow-up files to record the occurrence of delayed adverse reactions.

Every aspect of medical behavior should follow the principles of evidence-based medicine, and an individualized approach guided by professionals can maximize the achievement of treatment goals. Establishing a complete medication profile and monitoring system can help balance treatment effects and potential risks.